tiprankstipranks
pc:proly

Prolynx

Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. The Company is advancing a proprietary portfolio of extended-duration therapeutic candidates, targeting once monthly and once-quarterly dosing, optimized to smooth the peaks and troughs that can contribute to tolerability issues, and to support more consistent, long-term treatment.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 11, 2025
Series A
$70.00M

Investors

Investor Name
Funding Round
Series A
Series A

Related News and Analysis